Featured Publications
Consensus Curriculum for Fellowship Training in Multiple Sclerosis and Neuroimmunology
Hua LH, Obeidat AZ, Amezcua L, Cohen JA, Costello K, Dunn J, Gelfand JM, Goldman MD, Hopkins S, Jeffery D, Krieger S, Newsome SD, Shah S, Sicotte NL, Yadav V, Longbrake EE. Consensus Curriculum for Fellowship Training in Multiple Sclerosis and Neuroimmunology. Neurology Clinical Practice 2021, 11: 352-357. PMID: 34484933, PMCID: PMC8382436, DOI: 10.1212/cpj.0000000000001040.Peer-Reviewed Original ResearchMultiple sclerosisNeuroimmunologic disordersFellowship trainingNeuroimmune disordersTherapeutic optionsMore subspecialistsSubspecialty workforceSclerosisFellowship curriculumDisordersConsensus curriculumFellowship programsFuture training programsTraining programPatientsNeuroimmunologySubspecialistsCare
2024
Multicenter validation of automated detection of paramagnetic rim lesions on brain MRI in multiple sclerosis
Chen L, Ren Z, Clark K, Lou C, Liu F, Cao Q, Manning A, Martin M, Luskin E, O'Donnell C, Azevedo C, Calabresi P, Freeman L, Henry R, Longbrake E, Oh J, Papinutto N, Bilello M, Song J, Kaisey M, Sicotte N, Reich D, Solomon A, Ontaneda D, Sati P, Absinta M, Schindler M, Shinohara R, Cooperative T. Multicenter validation of automated detection of paramagnetic rim lesions on brain MRI in multiple sclerosis. Journal Of Neuroimaging 2024, 34: 750-757. PMID: 39410780, DOI: 10.1111/jon.13242.Peer-Reviewed Original ResearchParamagnetic rim lesionsArea under the curveRim lesionsMultiple sclerosisPrognosis of MSBiomarkers of chronic inflammationWhite matter lesionsMulticenter settingMulticenter studyMulticenter validationChronic inflammationBrain MRIClinical trialsIdentified lesionsMulticenterMS diagnosisLesionsParamagnetic rimAutomated segmentation methodMRIMRI biomarkersMulticenter datasetDiagnosisSclerosisTeam of trained ratersDiagnostic performance of central vein sign versus oligoclonal bands for multiple sclerosis
Toljan K, Daboul L, Raza P, Martin M, Cao Q, O’Donnell C, Rodrigues P, Derbyshire J, Azevedo C, Bar-Or A, Caverzasi E, Calabresi P, Cree B, Freeman L, Henry R, Longbrake E, Oh J, Papinutto N, Pelletier D, Samudralwar R, Schindler M, Sotirchos E, Sicotte N, Solomon A, Shinohara R, Reich D, Sati P, Ontaneda D. Diagnostic performance of central vein sign versus oligoclonal bands for multiple sclerosis. Multiple Sclerosis Journal 2024, 30: 1268-1277. PMID: 39234802, PMCID: PMC11421977, DOI: 10.1177/13524585241271988.Peer-Reviewed Original ResearchConceptsCentral vein signPositive predictive valueOligoclonal bandsDiagnostic performanceMS diagnosisCerebrospinal fluidMultiple sclerosisPredictive valueNegative predictive valueCerebrospinal fluid testingRadiological suspicionDiagnostic accuracyImaging biomarkersDiagnosisDiagnostic biomarkersMonthsSclerosisBiomarkersPilot studyBaselineSelection 3Impact of the COVID-19 Pandemic on the Personal Networks and Neurological Outcomes of People With Multiple Sclerosis: Cross-Sectional and Longitudinal Case-Control Study
Riley C, Venkatesh S, Dhand A, Doshi N, Kavak K, Levit E, Perrone C, Weinstock-Guttman B, Longbrake E, De Jager P, Xia Z. Impact of the COVID-19 Pandemic on the Personal Networks and Neurological Outcomes of People With Multiple Sclerosis: Cross-Sectional and Longitudinal Case-Control Study. JMIR Public Health And Surveillance 2024, 10: e45429. PMID: 38319703, PMCID: PMC10879979, DOI: 10.2196/45429.Peer-Reviewed Original Research
2023
A multicenter pilot study evaluating simplified central vein assessment for the diagnosis of multiple sclerosis
Daboul L, O’Donnell C, Amin M, Rodrigues P, Derbyshire J, Azevedo C, Bar-Or A, Caverzasi E, Calabresi P, Cree B, Freeman L, Henry R, Longbrake E, Oh J, Papinutto N, Pelletier D, Prchkovska V, Raza P, Ramos M, Samudralwar R, Schindler M, Sotirchos E, Sicotte N, Solomon A, Shinohara R, Reich D, Sati P, Ontaneda D. A multicenter pilot study evaluating simplified central vein assessment for the diagnosis of multiple sclerosis. Multiple Sclerosis Journal 2023, 30: 25-34. PMID: 38088067, PMCID: PMC11037932, DOI: 10.1177/13524585231214360.Peer-Reviewed Original ResearchConceptsCentral vein signMultiple sclerosisPositive lesionsInter-rater agreementDiagnosis of MSMagnetic resonance imaging (MRI) biomarkersDiagnostic performancePossible multiple sclerosisInter-rater reliability assessmentGood diagnostic performanceMcDonald criteriaMulticenter studyVein assessmentMean ageVein signImaging biomarkersLesionsMRI sequencesCharacteristic curveSclerosisPatientsDiagnosisAssessmentParticipantsOptimal methodSecondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: Pathogenesis, risk of infection, and disease management
Alvarez E, Longbrake E, Rammohan K, Stankiewicz J, Hersh C. Secondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: Pathogenesis, risk of infection, and disease management. Multiple Sclerosis And Related Disorders 2023, 79: 105009. PMID: 37783194, DOI: 10.1016/j.msard.2023.105009.Peer-Reviewed Original ResearchConceptsRisk of infectionCD20 therapySecondary hypogammaglobulinemiaMultiple sclerosisAnti-CD20 therapySerum immunoglobulin levelsB cell levelsDisease managementImmunoglobulin levelsSerious infectionsTherapy clinical trialsPotential complicationsClinical trialsHypogammaglobulinemiaPatientsTreatment approachesTherapyInfectionSclerosisRiskPossible mechanismMedicationsBest practice approachComplicationsPathogenesisEarly Treatment for Multiple Sclerosis
Longbrake E, Kalincik T. Early Treatment for Multiple Sclerosis. Neurology 2023, 101: 549-550. PMID: 37468283, DOI: 10.1212/wnl.0000000000207754.Peer-Reviewed Original ResearchImpact of the COVID-19 Pandemic on Personal Networks and Neurological Outcomes of People with Multiple Sclerosis (P12-3.001)
Venkatesh S, Riley C, Dhand A, Doshi N, Kavak K, Levit E, Perrone C, Weinstock-Guttman B, Longbrake E, De Jager P, Xia Z. Impact of the COVID-19 Pandemic on Personal Networks and Neurological Outcomes of People with Multiple Sclerosis (P12-3.001). Neurology 2023, 100 DOI: 10.1212/wnl.0000000000203369.Peer-Reviewed Original Research
2022
Toward Precision Phenotyping of Multiple Sclerosis
Pitt D, Lo CH, Gauthier SA, Hickman RA, Longbrake E, Airas LM, Mao-Draayer Y, Riley C, De Jager PL, Wesley S, Boster A, Topalli I, Bagnato F, Mansoor M, Stuve O, Kister I, Pelletier D, Stathopoulos P, Dutta R, Lincoln MR. Toward Precision Phenotyping of Multiple Sclerosis. Neurology Neuroimmunology & Neuroinflammation 2022, 9: e200025. PMID: 36041861, PMCID: PMC9427000, DOI: 10.1212/nxi.0000000000200025.Peer-Reviewed Original ResearchConceptsMultiple sclerosisSecondary progressive multiple sclerosisPathological processesProgressive multiple sclerosisKey pathological processClinical trial designDevelopment of biomarkersPerilesional inflammationNeuroaxonal degenerationMS phenotypeTrial designClinical importancePersonalized careM phenotypeSclerosisPhenotypeRemyelinationInflammationSyndromePrognosticationDegenerationProgressionBiomarkersCare
2020
Education Research: Multiple sclerosis and neuroimmunology fellowship training status in the United States
Obeidat AZ, Jassam YN, Hua LH, Cutter G, Ford CC, Halper J, Lisak RP, Sicotte NL, Longbrake EE. Education Research: Multiple sclerosis and neuroimmunology fellowship training status in the United States. Neurology 2020, 94: 10.1212/wnl.0000000000009096. PMID: 32107321, PMCID: PMC9246053, DOI: 10.1212/wnl.0000000000009096.Peer-Reviewed Original ResearchConceptsMS trainingMultiple sclerosisFellowship training statusProgram directorsDuration of trainingTraining statusMost programsSubspecialty certificationSclerosisUnited StatesNumber of fellowsTrainee educationFellowship programsQuestionnaireCurrent statusStatusCertification statusPostgraduate training
2019
Siponimod Chips Away at Progressive MS
Longbrake EE, Hafler DA. Siponimod Chips Away at Progressive MS. Cell 2019, 179: 1440. PMID: 31951523, PMCID: PMC8023412, DOI: 10.1016/j.cell.2019.11.034.Peer-Reviewed Original ResearchConceptsProgressive multiple sclerosisGadolinium-enhancing MRI lesionsInflammatory disease activityImmunomodulatory medicationsDisability progressionDisease activityMRI lesionsProgressive MSNeurologic disabilityPMS patientsMultiple sclerosisSiponimodMedicationsSclerosisPatientsLesionsBedsideProgressionCHAPTER 2 Genetics of Multiple Sclerosis
Abulaban A, Hafler D, Longbrake E. CHAPTER 2 Genetics of Multiple Sclerosis. 2019, 33-54. DOI: 10.1039/9781788016070-00033.ChaptersMultiple sclerosisCentral nervous systemImmune cell infiltratesComplex autoimmune diseaseEnvironmental risk factorsExtensive CNS demyelinationMS therapyAxonal damageCell infiltrateCNS demyelinationAutoimmune diseasesRisk factorsGenetic predispositionNervous systemDisease severityDiseaseSclerosisComplex genetic diseasesChapter 2 GeneticsGenetic diseasesDemyelinationInfiltratesAutoimmunityPathogenesisTherapy
2016
Efficacy and tolerability of oral versus injectable disease-modifying therapies for multiple sclerosis in clinical practice
Longbrake EE, Cross AH, Salter A. Efficacy and tolerability of oral versus injectable disease-modifying therapies for multiple sclerosis in clinical practice. Multiple Sclerosis Journal - Experimental Translational And Clinical 2016, 2: 2055217316677868. PMID: 28280599, PMCID: PMC5340186, DOI: 10.1177/2055217316677868.Peer-Reviewed Original ResearchDisease-modifying therapiesMultiple sclerosis activityInjectable disease-modifying therapiesOral disease-modifying therapiesMultiple sclerosisInjectable therapiesBaseline differencesClinical practiceRetrospective cohort studyProportional hazards modelDrug discontinuationCohort studyDiscontinuation ratesTreatment groupsHazards modelSclerosisPatientsTherapyRelative efficacyTolerabilityFurther studiesHigher proportionEfficacyExpert opinionTreatment
2014
Primary Central Nervous System Lymphoma Mimicking Multiple Sclerosis With Spontaneously Remitting Lesions (P5.172)
Longbrake E, Schmidt R, Cross A, Alvarez E. Primary Central Nervous System Lymphoma Mimicking Multiple Sclerosis With Spontaneously Remitting Lesions (P5.172). Neurology 2014, 82 DOI: 10.1212/wnl.82.10_supplement.p5.172.Peer-Reviewed Original Research
2013
Monoclonal Antibodies as Disease Modifying Therapy in Multiple Sclerosis
Longbrake EE, Parks BJ, Cross AH. Monoclonal Antibodies as Disease Modifying Therapy in Multiple Sclerosis. Current Neurology And Neuroscience Reports 2013, 13: 390. PMID: 24027005, PMCID: PMC3967547, DOI: 10.1007/s11910-013-0390-z.Peer-Reviewed Original Research
2009
Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis?
Longbrake EE, Racke MK. Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis? Expert Review Of Neurotherapeutics 2009, 9: 319-321. PMID: 19271940, DOI: 10.1586/14737175.9.3.319.Peer-Reviewed Original ResearchConceptsMultiple sclerosisRelapsing-remitting multiple sclerosisIL-12/ILPhase II clinical trialDose-ranging studyPhase I trialMechanism of actionRadiologic improvementAdvanced diseaseTherapy failsIL-23I trialIL-12/23IL-12Study inclusionPlacebo controlClinical trialsSubcutaneous injectionTreatment groupsAnimal modelsSclerosisPatientsAntibodiesTreatment effectsPhase II